MLEC

Moolec Science SA Ordinary Shares
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$5.62M
P/E Ratio
EPS
$-200.27
Beta
-0.32
52W High
$82.65
52W Low
$3.08
50-Day MA
$8.06
200-Day MA
$8.49
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Moolec Science SA Ordinary Shares

Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.

Official WebsiteUSAFY End: June

Fundamentals

Revenue (TTM)$7.83M
Gross Profit (TTM)-639,496
EBITDA$-8.07M
Operating Margin0.00%
Return on Equity-174.70%
Return on Assets-21.70%
Revenue/Share (TTM)$2.04
Book Value$0.70
Price-to-Book0.63
Price-to-Sales (TTM)0.01
EV/Revenue0.21
EV/EBITDA-1.01
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)948.00%
Shares Outstanding726,120
Float897,820
% Insiders21.06%
% Institutions2.28%

Historical Volatility

HV 10-Day
66.77%
HV 20-Day
55.29%
HV 30-Day
79.96%
HV 60-Day
97.75%
HV Rank

Volatility is currently contracting

Latest News

Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States

WARWICK, GB / ACCESS Newswire / May 14, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the 2026 commercial planting campaign for its GLASO1 safflower program focused on the production of high-GLA ("Gamma-Linolenic Acid") specialty oils for industrial and advanced ingredient applications. "Today represents a defining moment for Moolec.

Accesswire5/14/2026Neutral
Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications

WARWICK, UK / ACCESS Newswire / April 29, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced the successful completion of the first phase of industrialization of its GLASO1 safflower platform, following a 2025 campaign that materially exceeded all internal forecasts. Building on previously reported results confirming approximately 45% GLA ("Gamma-linolenic acid") concentration at commercial scale, the Company has now validated not only agronomic and processing performance, but also the industrial-scale handling and availability of high-purity GLA output, marking a critical step toward full commercial deployment.

Accesswire4/29/2026Neutral
Moolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seeds

WARWICK, GB / ACCESS Newswire / April 7, 2026 / Moolec Science Limited, a wholly owned subsidiary of Moolec Science SA (NASDAQ:MLEC) ("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced a significant scientific breakthrough in the production of animal proteins in plants. Through a sponsored research project with one of the most prestigious academic institutions in the United States of America, Moolec has successfully demonstrated the stable expression of bovine myoglobin, a heme-containing protein, within the seeds of the common pea (Pisum sativum).

Accesswire4/7/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026